Metabolic Diseases Pipeline Analysis:Focus on Dyslipidemia, Diabetes, and Obesity

Table of Contents

Executive Summary

• Which companies are the major players in the metabolic disease market?
• Which companies are the emerging players developing promising treatments for metabolic diseases?
• What is the commercial outlook for the metabolic disease market?

Chapter 1. Background of a Worldwide Epidemic

Chapter 2. Overview of Metabolic Diseases

• Type 2 Diabetes
• Obesity
• Dyslipidemia
• Metabolic Syndrome
• Non-Alcoholic Steatohepatitis
• Polycystic Ovarian Syndrome

Chapter 3. Current and Emerging Treatments for Metabolic Diseases

• Drugs Targeting Type 2 Diabetes
  • Insulin
    • Inhaled Insulin
    • Oral Insulin
  • Sulfonylurea Drugs
  • Meglitinides
  • Biguanides
  • Alpha-Glucosidase Inhibitors
  • PPAR Agonists (Thiazolidinediones)
  • Amylin Analogues
  • Incretin Mimetics
  • DPP-IV Inhibitors
  • SGLT2 Inhibitors
  • 11-Beta-HSD Type 1 Inhibitors
  • Beta-3 Adrenergic Agonists
• Drugs Targeting Obesity
  • Noradrenergic Anorectic Agents
  • Serotonin-Norepinephrine Reuptake Inhibitors. .
  • Lipase Inhibitors .
  • Melanin-Concentrating Hormone Receptor Antagonists .
  • Cannabinoid Antagonists
  • Neuropeptide Y Agonists
• Drugs Targeting Dyslipidemia
  • Statins (HMG-CoA Reductase Inhibitors) .
  • Fibric Acids
  • Bile Acid Sequestrants
  • Nicotinic Acid
  • Cholesterol Absorption Inhibitors .
  • Cholesteryl Ester Transferase Protein Inhibitors.
  • Squalene Synthase Inhibitors
  • Microsomal Triglyceride Transfer Protein Inhibitors
  • Acyl-CoA:Cholesterol Acyltransferase Inhibitors

Chapter 4. Company Profiles

• Abbott Laboratories
  • Currently Marketed Drugs for Metabolic Disorders
  • Drugs in Development
• Alizyme
  • Drugs in Development
• Amgen.
  • Drugs in Development
• Amylin Pharmaceuticals
  • Currently Marketed Drugs for Metabolic Disorders
  • Drugs in Development
• AstraZeneca
  • Currently Marketed Drugs for Metabolic Disorders
  • Drugs in Development
• Bristol-Myers Squibb
  • Currently Marketed Drugs for Metabolic Disorders
  • Drugs in Development
• Eli Lilly
  • Currently Marketed Drugs for Metabolic Disorders
  • Drugs in Development
• GlaxoSmithKline
  • Currently Marketed Drugs for Metabolic Disorders
  • Drugs in Development
• Isis Pharmaceuticals. .
  • Drugs in Development. .
• Ligand Pharmaceuticals .
  • Drugs in Development
• Merck & Co..
  • Currently Marketed Drugs for Metabolic Disorders
  • Drugs in Development
• Metabolex
  • Drugs in Development
• Novartis
  • Currently Marketed Drugs for Metabolic Disorders
  • Drugs in Development
• Novo Nordisk
  • Currently Marketed Drugs for Metabolic Disorders
• Pfizer
  • Currently Marketed Drugs for Metabolic Disorders
  • Drugs in Development
• Roche
  • Currently Marketed Drugs for Metabolic Disorders
  • Drugs in Development
• Sanofi-Aventis
  • Currently Marketed Drugs for Metabolic Disorders
  • Drugs in Development
• Schering-Plough
  • Currently Marketed Drugs for Metabolic Disorders

Chapter 5. Outlook for Metabolic Disease Therapeutics

Bibliography